Drug intelligence / Profile preview

HS-IT101

Development stage: Phase 2
Lead developer: Qingdao Sino-Cell Biomedicine Co., Ltd.
Modality: Cell Therapies
Administration: Intravenous

Overview

HS-IT101 (also known as FAST-TIL) is an autologous tumor-infiltrating lymphocyte (TIL) adoptive cell therapy developed by Qingdao Sino-Cell Biomedicine. It is characterized by an accelerated 14-day manufacturing process, which is significantly shorter than traditional TIL production timelines. The therapy is designed to treat advanced solid tumors, particularly melanoma that has become resistant to immune checkpoint inhibitors. The treatment protocol involves a non-myeloablative lymphodepletion regimen followed by the infusion of HS-IT101 and subsequent low-dose interleukin-2 (IL-2) administration to support T-cell expansion and persistence in vivo.

Brand names: FAST-TIL
Other names: FAST-TIL

Beyond the preview

Go deeper on HS-IT101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-IT101.

Explore the full profile